🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We show clinically relevant genomic alterations were significantly enriched in brain mets (BM) compared to local BCs & non-CNS metastases. Accessing ctDNA in CSF going to be key moving forward to understand & develop treatments to BMs ⁦npj Journals⁩ nature.com/articles/s4169…

Simultaneous Nature Medicine pub of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL. Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER. Waiting for EFS data, which will most likely impact practice. nature.com/articles/s4159…

Congrats to Kamran Ahmed & team on this important brain mets screening study! The cumulative incidence of brain mets among pts with HR+/HER2-ve mbc whose dz progressed on 1st line ET was quite high (23% @ 6 mo) & comparable to that of pts with HER2+ (24%) and triple neg mbc (25%).

BIG-NCTN is excited to collaborate with ABC Global Alliance on the brain Mets HUB! If you have suggestions for links/webpages to include, please send them to [email protected] where they will be curated as the HUB is built out. Seamus O’Reilly MD PhD Breast International Group Carey Anders

Out in The Lancet Oncology the OS results of the Young-PEARL trial With longer f.u., palbo + exemestane with OFS continued to show a significant benefit in PFS vs. capecitabine in premenopausal patients with HR+, HER2-neg mBC No OS benefit OncoAlert sciencedirect.com/science/articl…

Abstract submission for the 2025 SNO/ASCO CNS Metastases Conference is open! Deadline: Monday, March 31, 2025, 11:59 pm ET Abstracts will be published in an online supplement to the journal, Neuro-Oncology Advances. For full information visit soc-neuro-onc.org/SNOASCO2025

Congrats Katarzyna Jerzak, our Sunnybrook Health Sciences Centre breast cancer medical oncolgist, continues to interrogate associations and novel therapeutics for her2+ve disease. Check out the latest paper as we continue to learn about her2 low status and brain metastases. pubmed.ncbi.nlm.nih.gov/40048670/

Vepdegestrant demonstrates significant improvement in PFS in 2L in pts with ESR1m HR+ mBC (hazard ratio better than 0.60 targeted in the study). No significant benefit seen in ITT. First PROTAC with positive phase 3 data in breast cancer! pfizer.com/news/press-rel…

Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠 Happy to share that our work results from an international collaboration of young oncologists committed to advance cancer research👇🏻 OncoAlert thebreastonline.com/article/S0960-…

Very excited to see our work in press! link.springer.com/10.1245/s10434… Amanda Roberts Sonal Gandhi Katarzyna Jerzak, MD, MSc, FRCPC Natalie Coburn Julie Hallet

Ontario Health-Cancer Care Ontario takes a step towards further improving and standardizing the management of brain necroses following stereotactic radiosurgery by endorsing the ISRSy guideline published in the IJROBP - The Red Journal as open access. lnkd.in/dKcYF6gz.

This is unsurprising, given the success of T-DXd in HER2+ BC, but the question will now be “for how long” and possible if/when de-escalation strategies, knowing that many patients on THP were able to be on HP or H for a long time with near normal QoL. #bcsm

A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new options for our pts!

Today NEJM Challenging dogma for routine surveillance imaging after cancer treatment The results of 12 randomized trials show no survival benefit, despite scans leading to more chemotherapy, surgery and radiation nejm.org/doi/full/10.10…

T-DXd wins it all ✈️ This press release of DB-11 from industry announces significant ⬆️ in pCR with neoadjuvant T-DXd followed by THP in high-risk HER2+ #breastcancer Looking forward to the data 🔜 OncoAlert

Analysis of the BIG’s #ALTTO trial is presented by GRSrcr3, reporting long-term outcomes of pts w/ HER2-positive #breastcancer and rare special histologies in the ALTTO Ttrial. Go check 226P.

100% response rate??! Almost 90% 3 yr intracranial PFS! Amazing. So exciting to see decades of scientific advances pay off in meaningful ways

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

Happy to see these data presented at ASCO2025 now in JCO. I am not surprised. We use this approach in most of our patients who are on systemic therapy. I don't see the reason to target 1200 ml of normal brain with WBRT vs small cc cumulative tumor with SRS

🤔How can we ⬆️ access to innovation for ALL 🌎🌍🌏patients with #breastcancer Breast International Group 📝 npj Journals Free access link 👉rdcu.be/ev9HQ Successes of the past ✅ Pitfalls of the present ✅ Solutions for the future eg @Path4Young✅ 🙏to co-✍️& funders 💶